

Form 605Corporations Act 2001
Section 671B**Notice of ceasing to be a substantial holder**To Company Name/Scheme Viralytics LimitedACN/ARSN 010 657 351**1. Details of substantial holder(s)**Name Cormorant Global Healthcare Master Fund, LP, and their associates in Annexure A

ACN/ARSN (if applicable) _____

The holder ceased to be a
substantial holder on 9/01/2018The previous notice was given to the company on 29/11/2017The previous notice was dated 29/11/2017**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Persons votes affected
30 Nov 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$254,962	416,129 fully paid ordinary shares	416,129
30 Nov 2017	CRMA SPV, L.P.	On Market sale	\$51,388	83,871 fully paid ordinary shares	83,871
6 Dec 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$82,019	124,839 fully paid ordinary shares	124,839
6 Dec 2017	CRMA SPV, L.P.	On Market sale	\$16,531	25,161 fully paid ordinary shares	25,161
8 Dec 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$214,989	332,904 fully paid ordinary shares	332,904
8 Dec 2017	CRMA SPV, L.P.	On Market sale	\$43,331	67,096 fully paid ordinary shares	67,096
12 Dec 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$237,706	374,517 fully paid ordinary shares	374,517
12 Dec 2017	CRMA SPV, L.P.	On Market sale	\$47,909	75,483 fully paid ordinary shares	75,483
13 Dec 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$262,978	426,635 fully paid ordinary shares	426,635
13 Dec 2017	CRMA SPV, L.P.	On Market sale	\$53,003	85,988 fully paid ordinary shares	85,988
14 Dec 2017	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$59,945	99,908 fully paid ordinary shares	99,908

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
14 Dec 2017	CRMA SPV, L.P.	On Market sale	\$12,082	20,136 fully paid ordinary shares	20,136
9 Jan 2018	Cormorant Global Healthcare Master Fund, LP	On Market sale	\$224,641	286,605 fully paid ordinary shares	286,605

3. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Cormorant Global Healthcare Master Fund, LP	200 Clarendon St, 52 nd Floor, Boston, MA 02116, USA
CRMA SPV, L.P.	PO Box 309, Ugland House; Grand Cayman; KY1-1104 Cayman Islands

Signature

print name Neb Obradovic

capacity CCO

sign here

date January 11, 2018

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations of the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group. If the membership of each group with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 67B (7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 67B (4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has or may become entitled to in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate shares.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

This is Annexure "A" of 1 page referred to in the Form 605 signed by me and dated January 11, 2018.



Name: Nib Obradovic

Position: CCO

Date: January 11, 2018

Associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
CRMA SPV, L.P.	CRMA SVP, L.P.'s investment mandate is identical to that of Cormorant Global Healthcare Master Fund, LP and is conducted by the same investment manager, Cormorant Asset Management, LLC